Adult peoples with complicated urinary tract infections (cUTI) like pyelonephritis– a type of kidney infection caused by specific bacteria- suffer from many inconvenient problems like painful urination. It may lead to serious life threatening conditions including permanent kidney damage.
A robotic exoskeleton for the treatment of crouch (or flexed-knee) gait in children with cerebral palsy has been developed by US researchers from the Rehabilitation Medicine department of the NIH Clinical Centre.
The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland.
MedGenomeGenomics research and diagnostics company MedGenome said today that it closed a $30 million Series C round led by Sequoia India and Sofina. Zodius Capital, the co-founder & former CEO of Infosys, Kris Gopalakrishnan, and former Cognizant CEO Lakshmi Narayanan also participated in the round.
Chiesi's Holoclar, the first stem-cell therapy to be cleared by European regulators, has received a green light for use on the NHS in England and Wales to treat a rare sight condition.
Resonetics announced today its acquisition of Aduro Laser, an emerging leader in laser processing of tubular components for the medical device industry.
A "body-on-a-chip" device that can evaluate the side-effects of drugs on human cells has been developed by researchers at Kyoto University's Institute for Integrated Cell-Material Sciences, according to a study published today in the Royal Society of Chemistry Advances.
US regulators have approved the first and only treatment option to treat dyskinaesia in patients with Parkinson's disease.
A new anastomosis tool using a pair of medical magnets has been developed by researchers at the University of California, San Francisco, US.
Collaboration on an oncology drug discovery program was inked between Takeda Pharmaceutical, through its subsidiary Millennium Pharmaceuticals, and Molecular Templates.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.